Morten Otto Alexander Sommer

Morten Otto Alexander Sommer

Auto-generated profile, based on publicly available information

Morten Otto Alexander Sommer

Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2012 in Science
Verified
Journal Article
Closed access
PDF file
KFKevin Forsberg
Kevin Forsberg
AMAlejandro Reyes Muñoz
Alejandro Reyes Muñoz
BWBin Wang
Bin Wang
ESElizabeth M. Selleck
Elizabeth M. Selleck
MSMorten O. A. Sommer
Morten O. A. Sommer
GDGautam Dantas
Gautam Dantas
From Farm to Clinic?: Soil organisms have long been assumed to be an important source of antibiotic resistance genes, in part because of antibiotic-treated livestock and in part because of the natural ecology of antibiotic production in the soil. Forsberg et al. (p. 1107 ) developed a metagenomic protocol to assemble short-read sequence data after antibiotic selection experiments, using 12 different drugs in all antibiotic classes, and compared antibiotic resistance gene sequences between soil bacteria and clinically occurring pathogens. Sixteen sequences, representing seven gene products, were discovered in farmland soil bacteria within long stretches of perfect nucleotide identity with pathogenic proteobacteria.

25 September 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LILejla Imamovic
Lejla Imamovic
MSMorten O. A. Sommer
Morten O. A. Sommer
New drug deployment strategies are imperative to address the problem of drug resistance, which is limiting the management of infectious diseases and cancers. We evolved resistance in Escherichia coli toward 23 drugs used clinically for treating bacterial infections and mapped the resulting collateral sensitivity and resistance profiles, revealing a complex collateral sensitivity network. On the basis of these data, we propose a new treatment framework—collateral sensitivity cycling—in which drugs with compatible collateral sensitivity profiles are used sequentially to treat infection and select against drug resistance development. We identified hundreds of such drug sets and demonstrated that the antibiotics gentamicin and cefuroxime can be deployed cyclically such that the treatment regimen selected against resistance to either drug. We then validated our findings with related bacterial pathogens. These results provide proof of principle for collateral sensitivity cycling as a sustainable treatment paradigm that may be generally applicable to infectious diseases and cancer.

7 June 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
XJXinglin Jiang
Xinglin Jiang
MEMostafa M. Hashim Ellabaan
Mostafa M. Hashim Ellabaan
Pep CharusantiPep Charusanti
Pep Charusanti
CMChristian Munck
Christian Munck
KBKai Blin
Kai Blin
SLSang Yup Lee
Sang Yup Lee
It has been hypothesized that some antibiotic resistance genes (ARGs) found in pathogenic bacteria derive from antibiotic-producing actinobacteria. Here we provide bioinformatic and experimental evidence supporting this hypothesis. We identify genes in proteobacteria, including some pathogens, that appear to be closely related to actinobacterial ARGs known to confer resistance against clinically important antibiotics. Furthermore, we identify two potential examples of recent horizontal transfer of actinobacterial ARGs to proteobacterial pathogens. Based on this bioinformatic evidence, we propose and experimentally test a ‘carry-back’ mechanism for the transfer, involving conjugative transfer of a carrier sequence from proteobacteria to actinobacteria, recombination of the carrier sequence with the actinobacterial ARG, followed by natural transformation of proteobacteria with the carrier-sandwiched ARG. Our results support the existence of ancient and, possibly, recent transfers of ARGs from antibiotic-producing actinobacteria to proteobacteria, and provide evidence for a defined mechanism.

23 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MEMostafa M. H. Ellabaan
Mostafa M. H. Ellabaan
CMChristian Munck
Christian Munck
APAndreas Porse
Andreas Porse
LILejla Imamovic
Lejla Imamovic
MSMorten O. A. Sommer
Morten O. A. Sommer
Antibiotic resistance spreads among bacteria through horizontal transfer of antibiotic resistance genes (ARGs). Here, we set out to determine predictive features of ARG transfer among bacterial clades. We use a statistical framework to identify putative horizontally transferred ARGs and the groups of bacteria that disseminate them. We identify 152 gene exchange networks containing 22,963 bacterial genomes. Analysis of ARG-surrounding sequences identify genes encoding putative mobilisation elements such as transposases and integrases that may be involved in gene transfer between genomes. Certain ARGs appear to be frequently mobilised by different mobile genetic elements. We characterise the phylogenetic reach of these mobilisation elements to predict the potential future dissemination of known ARGs. Using a separate database with 472,798 genomes from Streptococcaceae, Staphylococcaceae and Enterobacteriaceae, we confirm 34 of 94 predicted mobilisations. We explore transfer barriers beyond mobilisation and show experimentally that physiological constraints of the host can explain why specific genes are largely confined to Gram-negative bacteria although their mobile elements support dissemination to Gram-positive bacteria. Our approach may potentially enable better risk assessment of future resistance gene dissemination.

4 May 2023 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
YGYilmaz Emre Gencay
Yilmaz Emre Gencay
DJDziuginta Jakociune
Dziuginta Jakociune
CRCamille Robert
Camille Robert
SSSzabolcs Semsey
Szabolcs Semsey
VMVirginia Martínez
Virginia Martínez
MSMorten Otto Alexander Sommer
Morten Otto Alexander Sommer
Antibiotic treatments have detrimental effects on the microbiome and lead to antibiotic resistance. To develop a phage therapy against a diverse range of clinically relevant Escherichia coli, we screened a library of 162 wild-type (WT) phages, identifying eight phages with broad coverage of E. coli, complementary binding to bacterial surface receptors, and the capability to stably carry inserted cargo. Selected phages were engineered with tail fibers and CRISPR–Cas machinery to specifically target E. coli. We show that engineered phages target bacteria in biofilms, reduce the emergence of phage-tolerant E. coli and out-compete their ancestral WT phages in coculture experiments. A combination of the four most complementary bacteriophages, called SNIPR001, is well tolerated in both mouse models and minipigs and reduces E. coli load in the mouse gut better than its constituent components separately. SNIPR001 is in clinical development to selectively kill E. coli, which may cause fatal infections in hematological cancer patients.

8 August 2016 in Molecular Biology and Evolution
Verified
Journal Article
Open access
PDF file
APAndreas Porse
Andreas Porse
KSKristian Schønning
Kristian Schønning
CMChristian Munck
Christian Munck
MSMorten O.A. Sommer
Morten O.A. Sommer
Large conjugative plasmids are important drivers of bacterial evolution and contribute significantly to the dissemination of antibiotic resistance. Although plasmid borne multidrug resistance is recognized as one of the main challenges in modern medicine, the adaptive forces shaping the evolution of these plasmids within pathogenic hosts are poorly understood. Here we study plasmid–host adaptations following transfer of a 73 kb conjugative multidrug resistance plasmid to naïve clinical isolates of Klebsiella pneumoniae and Escherichia coli. We use experimental evolution, mathematical modelling and population sequencing to show that the long-term persistence and molecular integrity of the plasmid is highly influenced by multiple factors within a 25 kb plasmid region constituting a host-dependent burden. In the E. coli hosts investigated here, improved plasmid stability readily evolves via IS26 mediated deletions of costly regions from the plasmid backbone, effectively expanding the host-range of the plasmid. Although these adaptations were also beneficial to plasmid persistence in a naïve K. pneumoniae host, they were never observed in this species, indicating that differential evolvability can limit opportunities of plasmid adaptation. While insertion sequences are well known to supply plasmids with adaptive traits, our findings suggest that they also play an important role in plasmid evolution by maintaining the plasticity necessary to alleviate plasmid–host constrains. Further, the observed evolutionary strategy consistently followed by all evolved E. coli lineages exposes a trade-off between horizontal and vertical transmission that may ultimately limit the dissemination potential of clinical multidrug resistance plasmids in these hosts.